Scott A. Kanner

Co-founder @stablixinc, cell biologist & training physician-scientist @ColumbiaPS. Opinions my own etc.

[Colecraft Lab @ColecraftL]

Ion channel inhibition by targeted recruitment of NEDD4-2 with divalent nanobodies https://t.co/35ShNlTvxy

[Scott A. Kanner @scottkanner]

@KhannaLabNYU @PNASNews Congrats!

[CACNA1A Foundation @cacna1a]

Stay tuned next week for updates from our #CACNA1A Research Roundtable w/50+ U.S. and intl researchers, clinicians, and reps from industry and @NIH discussing CACNA1A-related research, clinical trial readiness and strategies for moving drug development forward for our families.

[Stablix, Inc. @StablixInc]

How are we #TakingBOLDAction to pioneer targeted protein #deubiquitination therapeutics?

Tomorrow, Chief Scientific Officer @EddineSaiah will share how we're aiming to redefine #druggability during @WuXi_AppTec’s “BOLD: Innovation That Matters." Register: https://t.co/3qCDKwhNmT

[Scott A. Kanner @scottkanner]

A great milestone for #TPS and huge validation of the team, science and platform we have built @StablixInc! Thrilled to partner up with like-minded innovators @VertexPharma to bring new medicines to patients in need.

[Endpoints News @endpts]

Vertex signs deal with Stablix with exclusive license to certain molecules discovered using Stablix's protein stabilization platform.

https://t.co/YPtPzTbwu6

[Scott A. Kanner @scottkanner]

Excited to share this preprint! Targeted protein phosphorylation for ion channel complexes. Important implications for induced proximity modalities going beyond degradation/stabilization. https://t.co/disrzfU0PZ

[Peter Kolchinsky @PeterKolchinsky]

Congress is on the verge of gutting cancer & Alzheimer’s R&D w/ a few careless lines in reconciliation bill b/c seemingly everyone is tired of trying to do the right thing & thinks no one will notice.

You’ll never want to contribute to a campaign after this reading this. 1/20

[Michael Retchin @MichaelRetchin]

New York's @NucleateHQ Activator cohort will pitch their seed-stage ventures this week.

Join us Thursday, May 26, 1-5PM
(Free food + drinks & reception 5-7PM.)

RSVP: https://t.co/KmMmZjNEvk

[Scott A. Kanner @scottkanner]

@pippomancia @Nature @ColumbiaPS @comppaa @m_strent @pstansfeld @davidroper2 @OliBClarke @Khuram_U_Ashraf @RieNygaard Congrats everyone!!

[Scott A. Kanner @scottkanner]

Great science and great people! Exciting times ahead for @StablixInc

[Endpoints News @endpts]

Tony Kingsley is taking charge at Stablix, a biotech startup out of Versant that announced a $63 million launch raise just a couple of months before the biotech exec found the exit at Scholar Rock.

https://t.co/3d5FskEsXF

[Scott A. Kanner @scottkanner]

Couldn’t be more deserved. An outstanding mentor, scientist and friend. Go Henry!

[Professor Frances Separovic @FrancesBiophys]

Congratulations to the 2022 Cole Award winner, Henry Colecraft of @Columbia University in the City of New York: The #membrane Transport Subgroup will be celebrating Colecraft during the @BiophysicalSoc Annual Meeting #BPS2022.

[Scott A. Kanner @scottkanner]

Thanks so much!! Exciting road ahead #nycbiotech @HColecraft @ColumbiaPS @StablixInc

[Columbia Technology Ventures @Columbia_Tech]

Congratulations to Columbia scientists Dr. Henry Colecraft and Dr. @scottkanner on their startup's $63M Series A financing! https://t.co/ww4885Uf3J

[Scott A. Kanner @scottkanner]

@Orilieberman thanks ori!

[Scott A. Kanner @scottkanner]

Here's our website to learn more – we're hiring! https://t.co/pMYL6zkWZG

[Scott A. Kanner @scottkanner]

Excited to share the launch of our new company @StablixInc, pioneering a new class of medicines for targeted protein stabilization. Proud of our team and humbled by the opportunity to make a difference for patients. Here's to a new journey! #nycbiotech
https://t.co/3gswRW8CnI

[Zhaozhu Qiu @ZhaozhuQ]

Very excited to host Dr. Henry Colecraft tomorrow (4/7) at noon EST for @JHMIPhysiology Seminar @HopkinsMedicine! His lab has recently developed a great new tool to correct #ionchannels trafficking disorders, including cystic fibrosis. Please feel free to DM me for zoom link.

[Scott A. Kanner @scottkanner]

@AlexanderSisti @BrighamMedRes Go Alex!

[Scott A. Kanner @scottkanner]

@PhyllisTweets @YaleIMed Yeah Phyllis!!!!!

[Genetic Engineering & Biotechnology News @GENbio]

Researchers at @Columbia are developing engineered deubiquitinases (enDUBs) that can reverse the ubiquitination system’s ruthless machinations. Read more: https://t.co/DOSlv2YVUx

[Scott A. Kanner @scottkanner]

Our work was highlighted by Columbia!

[Columbia Vagelos College of Physicians & Surgeons @ColumbiaPS]

VP&S researchers Henry Colecraft, PhD, and @scottkanner have created a new technology using synthetic llama antibodies to protect endangered proteins inside cells. The technology could treat dozens of diseases. https://t.co/IHIyZO3yIV